Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Short-term Debt

Borrowings and the current portion of long-term debt due within one year.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Short-term Debt · Q2 FY2026 · quarter ended Jun 2026

Short-term debt of $2.04M in Q2 FY2026

Q2 FY2026 short-term debt was $2.04M.

Context

  • Short-term debt amounted to 1.6% of total assets at the end of Q2 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$2.04M+3.0% QoQ
Last fiscal yearDec 2025
$1.92M— YoY
Short-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Short-term Debt history

USD · from the balance sheet

Latest · FY2025
1.92M USD
Year-over-year change
—

Short-term Debt vs competitors

How ATTO compares with its peers on the latest reported figures

  • Peers report in different currencies, so short-term debt is compared through growth and share of total assets rather than absolute size.
  • Short-term debt amounts to 1.6% of total assets for ATTO, versus a peer median of 0.0%.
ATTO Competitors
Short-term Debt for ATTO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
QTTBQ32 Bio Inc.Mar 2026$6.24M USD+33.8%-40.2%9.8%
ANABAnaptysBio, Inc.Mar 2026$2.12M USD——0.6%
ATTOAttovia Therapeutics, Inc.Jun 2026$2.04M USD——1.6%
EVMNEvommune, Inc.Mar 2026$1.82M USD+143.9%—0.6%
ACRSAclaris Therapeutics, Inc.Mar 2026$569K USD——0.3%
ORKAOruka Therapeutics, Inc.Sep 2026$0 USD-100.0%+81.8%0.0%
MLTXMoonLake ImmunotherapeuticsMar 2026$0 USD——0.0%
ALMSAlumis Inc. Common StockJun 2026$0 USD——0.0%
AGMBAgomAb Therapeutics N.V. American Depositary SharesSep 2025€0 EUR——0.0%
ZURAZura Bio LimitedMar 2026$0 USD——0.0%
CNTBConnect Biopharma Holdings LimitedDec 2025$0 USD——0.0%
Peer median (excluding ATTO) —+33.8%+20.8%0.0%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.